Status:
COMPLETED
Neuronostatin - a Glucagonotropic Agent in Humans?
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborating Sponsors:
The Novo Nordisk Foundation Center for Basic Metabolic Research
Conditions:
Type 1 Diabetes
Hypoglycemia
Eligibility:
MALE
18-65 years
Phase:
NA
Brief Summary
With the present study the investigators wish to delineate the effects of neuronostatin-13 (NST) on glucose-dependent glucagon secretion in humans. The main question it aims to answer is: • What are ...
Detailed Description
With the present study the investigators wish to delineate the effects of neuronostatin on glucose-dependent glucagon secretion in humans. Thus, this study is designed to elucidate the physiological e...
Eligibility Criteria
Inclusion
- Normal haemoglobin \>8.3 mmol/l
- Normal fasting plasma glucose below 7 mmol/l
- Normal HbA1C \<42 mmol/mol (6%)
- Body mass index (BMI) 18.5-27 kg/m2
- Oral and written informed consent
Exclusion
- Diabetes
- Treatment with drugs that might interfere with glucose metabolism within a month prior to the research study
- Treatment with any medication that cannot be paused for 12 hours
- Known liver disease and/or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2 × normal values
- Nephropathy (eGFR \<60 ml/min and/or albuminuria)
- Any condition that the investigator feels would interfere with trial participation
Key Trial Info
Start Date :
December 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 25 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06143267
Start Date
December 6 2022
End Date
September 25 2024
Last Update
December 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Denmark, 2900